Biriz Nalan, Canturk Zerrin
Department of Pharmaceutical Microbiology, Institute of Health Sciences, Anadolu University, Eskisehir 26470, Turkey.
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, Turkey.
Asian Biomed (Res Rev News). 2024 Jun 28;18(3):133-145. doi: 10.2478/abm-2024-0019. eCollection 2024 Jun.
During breast cancer treatment, approximately half of the patients are prescribed psychotropic medication, such as selective serotonin reuptake inhibitors (SSRIs). Escitalopram oxalate is an SSRI used as an antidepressant.
In this study, by creating a breast cancer microenvironment with THP-1, MCF-7 and MDA-MB-231 breast cancer co-culture models were created.
MCF-7, MDA-MB-231, and THP-1 cell lines to determine the concentration range of the cytotoxic effect of escitalopram oxalate MTS and MTT test were used. IC values were determined by the xCELLigence real-time cell analysis (RTCA) system. Apoptotic activities and cytokine levels were determined by flow cytometry.
In the xCELLigence real-time analysis made according to the results, the IC value of escitalopram oxalate was measured as 13.7 μM for MCF-7 and 10.9 μM for MDA-MB-231. The IC value was measured as 54.6 μM for MCF-7 and 58.4 μM for MDA-MB-231 in xCELLigence analysis with tamoxifen. According to the MTS test results, the IC value of tamoxifen for THP-1 was 92.03 μM and the IC value for escitalopram oxalate was 95.32 μM. In the co-culture model, the immunological effects of escitalopram oxalate on MCF-7 cells were 2.8%, 11.1%, 15.6%, 10.6%, and 12.1% for interleukin (IL)-1β, IL-6, IL-8, IL-10, and TNF-α, respectively, while MDA effects on MB-231 cells, respectively, were 2.1%, 15.9%, 16.2%, 8.8%, and 11.8%.
According to the results obtained, it was concluded that the immunological effects of escitalopram oxalate are more effective than tamoxifen and that it can be used as an adjunctive agent in breast cancer treatment.
在乳腺癌治疗期间，约有一半的患者会被开具精神类药物，如选择性5-羟色胺再摄取抑制剂（SSRI）。草酸艾司西酞普兰是一种用作抗抑郁药的SSRI。
在本研究中，通过用THP-1细胞创建乳腺癌微环境，构建了MCF-7和MDA-MB-231乳腺癌共培养模型。
使用MCF-7、MDA-MB-231和THP-1细胞系，通过MTS和MTT试验确定草酸艾司西酞普兰细胞毒性作用的浓度范围。IC值通过xCELLigence实时细胞分析（RTCA）系统测定。通过流式细胞术测定凋亡活性和细胞因子水平。
根据结果进行的xCELLigence实时分析显示，草酸艾司西酞普兰对MCF-7的IC值测定为13.7μM，对MDA-MB-231的IC值为10.9μM。在用他莫昔芬进行的xCELLigence分析中，MCF-7的IC值测定为54.6μM，MDA-MB-231的IC值为58.4μM。根据MTS试验结果，他莫昔芬对THP-1的IC值为92.03μM，草酸艾司西酞普兰的IC值为95.32μM。在共培养模型中，草酸艾司西酞普兰对MCF-7细胞的免疫效应，对于白细胞介素（IL）-1β、IL-6、IL-8、IL-10和肿瘤坏死因子-α（TNF-α）分别为2.8%、11.1%、15.6%、10.6%和12.1%，而对MDA-MB-231细胞的效应分别为2.1%、15.9%、16.2%、8.8%和11.8%。
根据所获得的结果得出结论，草酸艾司西酞普兰的免疫效应比他莫昔芬更有效，并且它可以用作乳腺癌治疗的辅助药物。
